Three ways to work with the FDA for better patient-focused trials
Putting patients at the center of drug development allows us to design more efficient clinical trials that yield better data about a product’s risks and benefits. Companies that collaborate with the FDA can get direct feedback on their methodology and help build consensus on patient-relevant outcomes that might be accepted as proof of efficacy and safety.
This article covers three useful practices for getting the most out of your collaboration.
Related Insights
Video
Part 2: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Blog
Breaking through complex regulations and science speak – thinking “patients first” in lay language summary development
Jun 22, 2021
Blog
U.S. drug price reform of 2022: What does the Inflation Reduction Act mean for drug manufacturers?
Aug 17, 2022
Blog
Including patients in DCT design
Sep 13, 2022
Blog
Inclusion for all: Expanding trial accessibility for transgender and nonbinary patients
Sep 23, 2022
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
Whitepaper
Optimizing Biosensor-based Trials
Feb 1, 2023
Article
Relyvrio Approval: Lessons Learned
Oct 31, 2022
Blog
Taking a Proactive Approach to Post-Launch Patient Accessibility in Strategic Planning
Aug 4, 2022
Related Insights
Video
Part 2: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Blog
Breaking through complex regulations and science speak – thinking “patients first” in lay language summary development
Jun 22, 2021
Blog
U.S. drug price reform of 2022: What does the Inflation Reduction Act mean for drug manufacturers?
Aug 17, 2022
Blog
Including patients in DCT design
Sep 13, 2022
Blog
Inclusion for all: Expanding trial accessibility for transgender and nonbinary patients
Sep 23, 2022
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
Whitepaper
Optimizing Biosensor-based Trials
Feb 1, 2023
Article
Relyvrio Approval: Lessons Learned
Oct 31, 2022
Blog
Taking a Proactive Approach to Post-Launch Patient Accessibility in Strategic Planning
Aug 4, 2022